Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Frequency Therapeutics Inc (KRRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: KRRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $100.83
1 Year Target Price $100.83
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -56.28% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 145.46M USD | Price to earnings Ratio - | 1Y Target Price 100.83 |
Price to earnings Ratio - | 1Y Target Price 100.83 | ||
Volume (30-day avg) 10 | Beta - | 52 Weeks Range 10.29 - 98.00 | Updated Date 08/5/2025 |
52 Weeks Range 10.29 - 98.00 | Updated Date 08/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -981.18% |
Management Effectiveness
Return on Assets (TTM) -29.82% | Return on Equity (TTM) -60.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 75690721 | Price to Sales(TTM) 30.17 |
Enterprise Value 75690721 | Price to Sales(TTM) 30.17 | ||
Enterprise Value to Revenue 15.7 | Enterprise Value to EBITDA -5.6 | Shares Outstanding 9390490 | Shares Floating 4888127 |
Shares Outstanding 9390490 | Shares Floating 4888127 | ||
Percent Insiders 6.17 | Percent Institutions 104.25 |
Upturn AI SWOT
Frequency Therapeutics Inc
Company Overview
History and Background
Frequency Therapeutics Inc. was founded in 2014 and is focused on developing therapies to activate progenitor cells within the body to restore healthy tissue. They are focused on hearing loss treatment.
Core Business Areas
- Hearing Loss Therapeutics: Development of small molecule therapeutics to regenerate hair cells in the inner ear to treat sensorineural hearing loss.
Leadership and Structure
David L. Lucchino is the President and CEO. The company operates with a typical biotech organizational structure with research, development, and business operations departments.
Top Products and Market Share
Key Offerings
- FX-322: FX-322 is Frequency Therapeutics' lead drug candidate for sensorineural hearing loss. It is currently in clinical development. There is no market share data, but it is an experimental drug. Competitors include other companies developing hearing loss treatments, such as Decibel Therapeutics (DBTX).
Market Dynamics
Industry Overview
The hearing loss therapeutics industry is characterized by a large unmet need and growing aging population. Advancements in regenerative medicine are driving innovation.
Positioning
Frequency Therapeutics is positioned as a leader in regenerative medicine for hearing loss, focusing on activating inner ear progenitor cells. Their competitive advantage lies in their proprietary platform.
Total Addressable Market (TAM)
The hearing loss market is estimated to be in the billions of dollars. Frequency Therapeutics is positioned to capture a portion of this market with their regenerative approach, assuming successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary platform technology for activating progenitor cells
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Dependence on success of lead candidate FX-322
- High cash burn rate
- Clinical trial risk and regulatory hurdles
Opportunities
- Positive clinical trial results for FX-322
- Partnerships with pharmaceutical companies
- Expansion of pipeline into other regenerative medicine applications
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Regulatory challenges
Competitors and Market Share
Key Competitors
- DBTX
Competitive Landscape
Frequency Therapeutics faces competition from companies with alternative approaches to treating hearing loss. Their regenerative medicine approach is a differentiator but also carries risk.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by research and development advancements, not revenue growth.
Future Projections: Future growth depends on clinical trial success and regulatory approvals for FX-322. Analyst estimates depend heavily on these milestones.
Recent Initiatives: Recent initiatives focus on advancing FX-322 through clinical trials and exploring partnerships.
Summary
Frequency Therapeutics is a high-risk, high-reward biotech company focused on regenerative medicine for hearing loss. The company is focused on FX-322, and its future depends on its success. Clinical trials and regulatory hurdles pose significant risks to their business model, but successful commercialization would be a game changer. They must secure further funding or partnerships to survive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. The data presented is based on publicly available information and may be subject to change. Market share numbers are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Frequency Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2023-11-06 | CEO, President & Director Dr. Ram Aiyar MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 112 | Website https://www.korrobio.com |
Full time employees 112 | Website https://www.korrobio.com | ||
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.